Alnylam Pharmaceuticals Overview
Alnylam Pharmaceuticals Target Price
See Alnylam Pharmaceuticals's analyst price targets ($370) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$219.72
Average Target Price
$368.39
67.7% upside
67.7% upside18 analysts in the last 4 months
High: $485 | Low: $230
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-09-08 | Jefferies | $260 | 18.3% upside |  |
| 2026-08-28 | Jefferies | $230 | 4.7% upside | |
| 2026-08-25 | BernsteinJeffrey Walch | $376 | 71.1% upside | |
| 2026-08-18 | BMO Capital | $318 | 44.7% upside | |
| 2026-08-14 | Wells FargoDerek Archila | $256 | 16.5% upside | |
| 2026-08-04 | H.C. Wainwright | $455 | 107.1% upside | |
| 2026-08-04 | Truist Financial | $315 | 43.4% upside | |
| 2026-08-03 | BarclaysEliana Merle | $450 | 104.8% upside | |
| 2026-07-31 | Raymond JamesMartin Auster | $420 | 91.2% upside | |
| 2026-07-31 | RBC CapitalLuca Issi | $350 | 59.3% upside | |
| 2026-07-31 | Oppenheimer | $350 | 59.3% upside | |
| 2026-07-31 | Morgan Stanley | $300 | 36.5% upside | |
| 2026-07-31 | Stifel NicolausPaul Matteis | $318 | 44.7% upside | |
| 2026-07-13 | H.C. Wainwright | $485 | 120.7% upside | |
| 2026-07-13 | Truist Financial | $410 | 86.6% upside | |
| 2026-07-10 | Morgan Stanley | $400 | 82% upside | |
| 2026-07-09 | Raymond James | $468 | 113% upside | |
| 2026-06-29 | H.C. Wainwright | $470 | 113.9% upside | |
| 2026-05-01 | Morgan Stanley | $370 | 68.4% upside | |
| 2026-05-01 | Bernstein | $447 | 103.4% upside | |
| 2026-02-17 | Canaccord Genuity | $429 | 95.2% upside | |
| 2026-02-13 | Morgan Stanley | $360 | 63.8% upside | |
| 2026-02-13 | Bernstein | $451 | 105.3% upside | |
| 2026-02-13 | Chardan Capital | $425 | 93.4% upside | |
| 2026-02-12 | Stifel NicolausPaul Matteis | $444 | 102.1% upside | |
| 2026-01-30 | H.C. Wainwright | $510 | 132.1% upside | |
| 2026-01-20 | RBC Capital | $465 | 111.6% upside | |
| 2026-01-20 | Wells Fargo | $376 | 71.1% upside | |
| 2026-01-12 | Needham | $529 | 140.8% upside | |
| 2026-01-12 | Raymond JamesMartin Auster | $472 | 114.8% upside | |
| 2026-01-08 | Truist Financial | $530 | 141.2% upside | |
| 2026-01-06 | Bernstein | $491 | 123.5% upside | |
| 2025-12-15 | Leerink PartnersMani Foroohar | $351 | 59.7% upside | |
| 2025-12-11 | Stifel Nicolaus | $508 | 131.2% upside | |
| 2025-11-04 | H.C. WainwrightPatrick Trucchio | $570 | 159.4% upside | |
| 2025-10-31 | Barclays | $527 | 139.9% upside | |
| 2025-10-31 | OppenheimerLeland Gershell | $500 | 127.6% upside | |
| 2025-10-31 | Chardan CapitalKeay Nakae | $475 | 116.2% upside | |
| 2025-10-30 | UBS | $549 | 149.9% upside | |
| 2025-10-30 | Morgan StanleyMichael Ulz | $495 | 125.3% upside | |
| 2025-10-22 | Cantor Fitzgerald | $450 | 104.8% upside | |
| 2025-10-17 | Truist Financial | $535 | 143.5% upside | |
| 2025-10-06 | Morgan StanleyMichael Ulz | $475 | 116.2% upside | |
| 2025-10-06 | Stifel NicolausPaul Matteis | $495 | 125.3% upside | |
| 2025-09-05 | BMO CapitalKostas Biliouris | $470 | 113.9% upside | |
| 2025-07-29 | Raymond James | $370 | 68.4% upside | |
| 2025-07-21 | Truist FinancialDanielle Brill | $385 | 75.2% upside | |
| 2025-06-24 | BMO CapitalKostas Biliouris | $360 | 63.8% upside | |
| 2025-03-21 | Scotiabank | $338 | 53.8% upside | |
| 2025-01-07 | BernsteinWilliam Pickering | $310 | 41.1% upside | |